Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan
Background: Intravenous amiodarone is considered to be the first-line drug for the treatment of ventricular tachycardia or fibrillation. However, in Japan, nifekalant had been used before the introduction of amiodarone; therefore, most clinical studies on amiodarone use have been small-scale studies...
Main Authors: | Mari Amino, MD, PhD, Koichiro Yoshioka, MD, PhD, Shigetaka Kanda, MD, Yoshiaki Deguchi, MD, PhD, Mari Nakamura, MD, Yoshinori Kobayashi, MD, PhD, Sadaki Inokuchi, MD, PhD, Teruhisa Tanabe, MD, PhD, Yuji Ikari, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-06-01
|
Series: | Journal of Arrhythmia |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1880427613001592 |
Similar Items
-
Erratum to “Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan” [J. Arrhythm. 30 (2014) 180–185]
by: Mari Amino, MD, PhD, et al.
Published: (2014-10-01) -
Coronary Artery and Right Ventricular Perforation Due to Mechanical CPR Trauma
by: David Elison, MD, et al.
Published: (2019-10-01) -
Outcome of consistent guideline-based tricuspid management in patients undergoing degenerative mitral regurgitation correctionCentral MessagePerspective
by: Gilles D. Dreyfus, MD, PhD, et al.
Published: (2021-09-01) -
Efficacy of a pure Ikr blockade with nifekalant in refractory neonatal congenital junctional ectopic tachycardia and careful attention to damaging the atrioventricular conduction during the radiofrequency catheter ablation in infancy
by: Hisaaki Aoki, MD, PhD, et al.
Published: (2017-06-01) -
Why the Norwegian 2021 guideline for basic life support are different
by: Conrad Arnfinn Bjørshol, et al.
Published: (2023-06-01)